NEW YORK, NY / ACCESSWIRE / August 4th, 2014 / EquitiesIQ, a leading informational research provider, has provided an update to its coverage of Advaxis, Inc. (Nasdaq: ADXS). Advaxis is an emerging biopharmaceutical company developing proprietary Lm-LLO immunotherapies for the treatment of cancer.
MEDI4736 is designed to counter the tumour's immune-evading tactics by blocking a signal that helps tumours avoid detection, while ADXS-HPV enhances the ability of immune cells to combat the tumour. Preclinical evidence suggests that the combination of ADXS-HPV with a checkpoint inhibitor, such as MEDI4736, could enhance overall anti-tumour response.
Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
Get the Advaxis Update: http://equitiesiq.com/advaxis-update-3
Important Disclosures and Disclaimers
The research report is not an offer or solicitation to buy or sell the securities of the Advaxis. The report is for information purposes only, and is not intended to (and is provided explicitly on the condition that it not) be used as the sole basis to make any investment decision. Investors should make their own determinations whether an investment in any particular security is consistent with their investment objectives, risk tolerance, and financial situation. EquitiesIQ and its affiliates are not recommending any investments based on the information in the research report.
This press release and the research report contain forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. EquitiesIQ does not guarantee the accuracy and comprehensiveness of these predictions. You should not invest in the Advaxis in reliance on these forward-looking statements.
Please read the full disclosures and disclaimers at the end of our reports as well as the general disclaimers and terms at EquitiesIQ.com/Disclaimer.